Download PDF
Thromb Haemost 1997; 78(03): 1088-1092
DOI: 10.1055/s-0038-1657691
Rapid Communication
Schattauer GmbH Stuttgart

Antithrombin Acts as a Negative Acute Phase Protein as Established with Studies on HepG2 Cells and in Baboons

R W L M Niessen
1   The Center for Hemostasis, Thrombosis, Atherosclerosis and Inflammation Research, Amsterdam, The Netherlands
2   The EKZ/Children's AMC, Amsterdam, The Netherlands
,
R J Lamping
1   The Center for Hemostasis, Thrombosis, Atherosclerosis and Inflammation Research, Amsterdam, The Netherlands
,
P M Jansen
4   The Department of Autoimmune Disease, Central Laboratory of the Netherlands Blood Transfusion Service, Amsterdam, The Netherlands
,
M H Prins
3   The Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, Amsterdam, The Netherlands
,
M Peters
2   The EKZ/Children's AMC, Amsterdam, The Netherlands
,
F B Taylor Jr.
6   The Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, USA
,
J J M de Vijlder
2   The EKZ/Children's AMC, Amsterdam, The Netherlands
,
J W ten Cate
1   The Center for Hemostasis, Thrombosis, Atherosclerosis and Inflammation Research, Amsterdam, The Netherlands
,
C E Hack
4   The Department of Autoimmune Disease, Central Laboratory of the Netherlands Blood Transfusion Service, Amsterdam, The Netherlands
,
A Sturk
5   The Department of Clinical Chemistry, Academic Hospital Leiden, Leiden, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 24 1997

Accepted 12 May 1997

Publication Date:
12 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Patients with sepsis or after major surgery have decreased plasma levels of the anticoagulant protein antithrombin. In such patients elevated levels of interleukin-6 (IL-6) are present and this interleukin is known to induce positive and negative acute phase responses. To investigate the possibility that antithrombin acts as a negative acute phase response-protein we performed studies on the human hepatoma cell line HepG2 in vitro and baboons in vivo. HepG2 cells were treated with recombinant human IL-6, ILß3, or combinations of the latter two, and tested for production of antithrombin, fibrinogen and prealbumin (transthyretin). This treatment resulted in a dose dependent increase in fibrinogen concentration (with a maximum effect of 2.8-2.9-fold) and a dose dependent decrease in prealbumin (with a maximum effect of 0.6-0.7-fold) and antithrombin concentrations (with a maximum effect of 0.6-0.8-fold). Simultaneous treatment of the HepG2 cells with IL-6 (1,000 pg/ml or 2,500 pg/ml) and IL-1β (25 pg/ml), provided more extensively decreased prealbumin (0.8 and 0.6-fold, respectively) and antithrombin concentration (0.7 and 0.6-fold, respectively) compared to the single interleukin treatment at these concentrations. Baboons treated with 2 µg IL-6 · kg body-weight-1 · day1 showed increased plasma CRP levels (59-fold, p <0.05) and decreased prealbumin (0.9-fold, p <0.05) and antithrombin (0.8-fold, p <0.05) plasma levels, without evidence for coagulation activation. Our results indicate that antithrombin acts as a negative acute phase protein, which may contribute to the decreased antithrombin plasma levels observed after major surgery or in sepsis.

 

  • References

  • 1 Scientific and Standardization Committee Communications. Nomenclature of quantities and units in thrombosis and haemostasis (recommendation 1993). Thromb Haemost 1994; 71: 375-394
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Rosenberg RD, Damus PS. The purification and mechanism of antithrom bin-heparin cofactor. J Biol Chem 1973; 248: 6490-6505
    PubMedGoogle Scholar
  • 3 Buchanan MR, Boneu B, Ofosu F, Hirsch J. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin. Blood 1985; 65: 198-201
    PubMedGoogle Scholar
  • 4 Schipper HG, Roos J, van de Meulen, ten Cate JW. Antithrombin III de ficiency in surgical intensive care patients. Thromb Res 1981; 21: 73-80
    CrossrefPubMedGoogle Scholar
  • 5 Biiller HR, Bolwerk C, ten Cate J, Roos J, Kahlé HL, ten Cate JW. Post operative hemostatic profile in relation to gram-negative septicemia. Crit CareMed 1982; 10: 311-315
    PubMedGoogle Scholar
  • 6 Brandtzaeg P, Sandset PM, Joo GB, Ovstebo R, Abildgaard U, Kierulf P. The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococ cal disease. Thromb Res 1989; 55: 459-470
    CrossrefPubMedGoogle Scholar
  • 7 Koj A. Definition and classification of acute-phase proteins. in: The acute phase response to injury and infection. Gordon AH, Koj A. (eds). Amster dam: Elsevier; 1985. pp 139-232
    Google Scholar
  • 8 Adams DO, Hamilton TA. The cell biology of macrophage activation. Annu Rev Immunol 1984; 2: 283-318
    CrossrefPubMedGoogle Scholar
  • 9 Darlington GJ, Wilson DR, Lachman LB. Monocyte-conditioned medium, interleukin 1, and tumor necrosis factor stimulate the acute phase response in human hepatoma cells in vitro. J Cell Biol 1986; 103: 787-93
    CrossrefPubMedGoogle Scholar
  • 10 Perlmutter DH, Dinarello CA, Punsai PI, Colten HR. Cachectin/tumor necrosis factor regulates hepatic acute-phase gene expression. J Clin Invest 1986; 78: 1349-54
    CrossrefPubMedGoogle Scholar
  • 11 Dinarello CA. Interleukin-1 and the pathogenesis of the acute-phase response. New Engl J Med 1984; 311: 1413-8
    CrossrefPubMedGoogle Scholar
  • 12 Hack CE, de GrootER, Felt-Bersma RJF, Nuijens JH, Strack vanSchijndel, Eerenberg BelmerA, Thijs LG, Aarden LA. Increased plasma lev els of interleukin-6 in sepsis. Blood 1989; 74: 1704-1710
    PubMedGoogle Scholar
  • 13 Wortel CH, van DeventerJH, Aarden LA, Lygidakis NJ, Biiller HR, Hoek JF, Horikx J, ten Cate JW. Interleukin-6 mediates host defense responses induced by abdominal surgery. Surgery 1993; 114: 564-570
    PubMedGoogle Scholar
  • 14 Gauldie J, Richards C, Hamish D, Lansdorp P, Baumann H. Interferon β2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 1987; 84: 7251-7255
    CrossrefPubMedGoogle Scholar
  • 15 Castell JV, Gomez LechonM, David M, Andus T, Geiger T, Trullenque R, Farba R, Heinrich PC. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 1989; 242: 237-239
    CrossrefPubMedGoogle Scholar
  • 16 Morrone G, Ciliberto G, Oliviero S, Arcone R, Dente L, Content J, Cortese R. Recombinant interleukin 6 regulates the transcriptional activation of a set of human acute phase genes. J Biol Chem 1988; 263: 12554-12558
    PubMedGoogle Scholar
  • 17 Marinkovic S, Jahreis GP, Wong GG, Baumann H. IL-6 modulates the syn thesis of a specific set of acute phase plasma proteins in vivo. J Immunol 1989; 142: 808-812
    PubMedGoogle Scholar
  • 18 Yap SH, Moshage HJ, Hazenberg BPC, Roelofs HMJ, Bijzet J, Limburg PC, Aarden LA, van RijswijkMH. Tumor necrosis factor (TNF) inhibits interleukin (IL)-l and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepato cytes. Biochim Biophys Acta 1991; 1091: 405-408
    CrossrefPubMedGoogle Scholar
  • 19 Dofferhoff ASM, de Jong HJ, Bom VJJ, van der MeerJ, Limburg PC, de Vries-Hospers HG, Marrink J, Mulder POM, Weits J. Complement activation and the production of inflammatory mediators during the treatment of severe sepsis in humans. Scand J Infect Dis 1992; 24: 197-204
    CrossrefPubMedGoogle Scholar
  • 20 Knowles BB, Howe CC, Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 1980; 209: 491-499
    CrossrefPubMedGoogle Scholar
  • 21 Niessen RWLM, Pfaffendorf BA, Sturk A, Lamping RJ, Schaap MCL, Hack CE, Peters M. The influence of insulin, B-estradiol, dexamethasone and thyroid hormone on the secretion of coagulant and anticoagulant proteins by HepG2 cells. Thromb Haemost 1995; 74: 686-692
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Baumann H, Richards C, Gauldie J. Interaction among hepatocyte-stimulating factors, interleukin 1, and glucocorticoids for regulation of acute phase plasma proteins in human hepatoma (HepG2) cells. J Immunol 1987; 139: 4122-4128
    PubMedGoogle Scholar
  • 23 Bartalena L, Farsetti A, Flink IL, Robbins J. Effects of interleukin-6 on the expression of thyroid hormone-binding protein genes in cultured human hepatoblastoma-derived (HepG2) cells. Mol Endocrinol 1992; 06: 935-942
    PubMedGoogle Scholar
  • 24 De BoerJP, Abbink JJ, Brouwer MC, Meijer C, Roem D, Voorn GP, Lambers JWJ, vffi MourikJA, Hack CE. PAI-I synthesis in the human hepatoma cell line HepG2 is increased by cytokines Evidence that the liver contributes to acute phase behaviour of PAI-I. Thromb Haemost 1991; 65: 181-185
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Le J, Vilcek J. Interleukin 6: A multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest 1989; 61: 588-602
    PubMedGoogle Scholar
  • 26 Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265: 621-636
    CrossrefPubMedGoogle Scholar
  • 27 Stathakis N, Papayannis AG, Gardikas CD. Postoperative antithrombin III concentration. Lancet 1973; 01: 430
    PubMedGoogle Scholar
  • 28 Aberg M, Nilsson IM, Hedner U. Antithrombin III after operation. Lancet 1973; 02: 1337 (letter).
    PubMedGoogle Scholar